No therapy has demonstrated comparable reductions in cardiovascular and overall mortality in T2DM patients with proven cardiovascular risk to date in either a dipeptidyl peptidase-4 (DPP-4) inhibitor or a glucagon-like peptide-1 (GLP-1) [7]. Here, GCG is linked to type 2 diabetes mellitus.